FBXO6 controls the degradation of checkpoint kinase 1 (Chk1) and confers the sensitivity to certain anticancer drugs, including camptothecin, in tumor cells, such as non-small cell lung cancer, GBM, and breast cancer (113). This evidence concerns the gene FBXO6 and non-small cell lung carcinoma.